Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 10/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 10/20 | 0.34 |
| ▸ | ITGAL | P20701 | 10/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095426 | 0.88 | CASR (0.43) | — | |
| SCHEMBL1105877 | 0.85 | HRH3 (0.39) | HMOX1HSD17B2 | |
| SCHEMBL1096953 | 0.83 | CASR (0.42) | CCR5 | |
| SCHEMBL1105957 | 0.80 | CASR (0.44) | — | |
| SCHEMBL1105799 | 0.79 | HSD17B2 (0.37) | HTR1AHTR7HSD17B2CCR5 | |
| SCHEMBL1105813 | 0.79 | CXCR3 (0.38) | HSD17B2 | |
| SCHEMBL1105819 | 0.79 | CASR (0.47) | HTR1AHTR7HSD17B2 | |
| SCHEMBL1105776 | 0.78 | CASR (0.45) | HTR1AHTR7HSD17B2 | |
| SCHEMBL1105800 | 0.78 | CASR (0.38) | HTR1AHSD17B2RBP4TTR | |
| SCHEMBL1105787 | 0.78 | KDM1A (0.41) | HTR7HSD17B2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | HMOX1 3921/4885HTR1A 1308/4885ITGB2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.